Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT02277197 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Squamous Cell of Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma, Head And Neck

Interventions

DRUG: Ficlatuzumab
DRUG: Cetuximab

Sponsor

James J Lee

Collaborators

[object Object]